Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for chinese renal transplant recipients

Transplantation Proceedings

Volumn 42, Issue 9, 2010, Pages 3459-3464

  Zhang, J ^a   Zhang, X ^a   Liu, L ^b   Tong, W ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Second Artillery General Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CHINESE; CLINICAL ARTICLE; DNA SEQUENCE; DOSE CALCULATION; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CHINA; CYTOCHROME P-450 CYP3A; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GENE FREQUENCY; GENETIC TESTING; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; STEROIDS; TACROLIMUS; YOUNG ADULT;

EID: 78649490852     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.06.028     Document Type: Article

References (23)

1. L.J. Scott, K. McKeage, and S.J. Keam Tacrolimus: a further update of its use in the management of organ transplantation Drugs 63 2003 1247
2. I.A. MacPhee, S. Fredericks, and T. Tai The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation Am J Transplant 4 2004 914
3. M. Sattler, F.P. Guengerich, and C.H. Yun Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat Drug Metab Dispos 20 1992 753
4. C. Rosso Felipe, T.V. de Sandes, and E.L. Sampaio Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs Transplant Proc 41 2009 1441
5. J.K. Lamba, Y.S. Lin, and E.G. Schuetz Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 54 2002 1271
6. D.A. Hessenlink, R.H. van Schaik, and I.P. van der Heiden Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 2003 245
7. R. Grenda, S. Prokurat, and A. Ciechanowicz Evaluation of the genetic background of standard-immunosuppressantrelated toxicity in a cohort of 200 paediatric renal allograft recipientsa retrospective study Ann Transplant 14 2009 18
8. X. Zhang, Z.H. Liu, and J.M. Zheng Influence of CYP3A5 and MDR1 polymorphisms on 6 tacrolimus concentration in the early stage after renal transplantation Clin Transplant 19 2005 638
9. N. Tsuchiya, S. Satoh, and H. Tada Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplantation 78 2004 1182
10. A. Provenzani, M. Notarbartolo, and M. Labbozzetta The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients Ann Transplant 14 2009 23
11. P.T. Loh, H.X. Lou, and Y. Zhao Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients Transplant Proc 40 2008 1690
12. S. Satoh, M. Saito, and T. Inoue CYP3A5 (*)1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients Eur J Clin Pharmacol 65 2009 473
13. Y. Dai, M.F. Hebert, and N. Isoherranen Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro Drug Metab Dispos 34 2006 836
14. Y. Zhao, M. Song, and D. Guan Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus Transplant Proc 37 2005 178
15. M.A. Willrich, M.H. Hirata, and F.D. Genvigir CYP3A5 (*)3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia Clin Chim Acta 398 2008 15
16. J.S. Chen, L.S. Li, and D.R. Cheng Effect of CYP3A5 genotype on renal allograft recipients 7 treated with tacrolimus Transplant Proc 41 2009 1557
17. J. Larriba, N. Imperiali, and R. Groppa Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients Transplant Proc 42 2010 257
18. L. Barrera-Pulido, I. Aguilera-Garca, and F. Docobo-Pérez Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients Transplant Proc 40 2008 2949
19. R. Singh, A. Srivastava, and R. Kapoor Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India Naunyn Schmiedebergs Arch Pharmacol 380 2009 169
20. L.C. Teng, C.X. Wang, and L.Z. Chen Effect of CYP3A5 polymorphism on tacrolimus concentration during early period after kidney transplantation in recipients Zhong Hua Qi Guan Yi Zhi Za Zhi 30 2009 261
21. J. Du, Y.F. Xu, and S.W. Duan A case-control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population Prog Neuropsychopharmacol Biol Psychiatry 33 2009 1200
22. L. Renders, M. Frisman, and M. Ufer CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients Clin Pharmacol Ther 81 2007 228
23. V. Haufroid, P. Wallemacq, and V. VanKerckhove CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study Am J Transplant 6 2006 2706